{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T23:06:37Z","timestamp":1768518397347,"version":"3.49.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11882-024-01188-0","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T05:10:25Z","timestamp":1738127425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hypersensitivity Reactions to Anticonvulsants"],"prefix":"10.1007","volume":"25","author":[{"given":"Unaiza","family":"Faizan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"issue":"23","key":"1188_CR1","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJM195006082422304","volume":"242","author":"BH Chaiken","year":"1950","unstructured":"Chaiken BH, Goldberg BI, Segal JP. Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med. 1950;242(23):897\u20138.","journal-title":"N Engl J Med"},{"key":"1188_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/archinte.1948.00220230003001","volume":"81","author":"JJ VanWyk","year":"1948","unstructured":"VanWyk JJ. Hoffmann CR Periarteritis nodosa: A case of fatal exfoliative dermatitis resulting from \u201cdilantin sodium\u201d sensitization. Arch Intern Med. 1948;81:605.","journal-title":"Arch Intern Med"},{"issue":"6","key":"1188_CR3","first-page":"421","volume":"22","author":"T Nagata","year":"1992","unstructured":"Nagata T, Kawamura N, Motoyama T, et al. A case of hypersensitivity syndrome resembling Langerhans cell histiocytosis during phenobarbital prophylaxis for convulsion. Jpn J Clin Oncol. 1992;22(6):421\u20137.","journal-title":"Jpn J Clin Oncol"},{"key":"1188_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11882-002-0035-9","volume":"2","author":"O Bessmertny","year":"2002","unstructured":"Bessmertny O, Pham T. Antiepileptic hypersensitivity syndrome: clinicians beware and be aware. Curr AllergyAsthma Rep. 2002;2:34\u20139.","journal-title":"Curr AllergyAsthma Rep"},{"key":"1188_CR5","doi-asserted-by":"crossref","unstructured":"Handoko KB, van Puijenbroek EP, Bijl AH, Hermens WA, Zwart-van Rijkom JE, Hekster YA, Egberts TC. Influence of chemical structure on hypersensitivity reactions induced by antiepileptic drugs: the role of the aromatic ring. Drug Safety. 2008;31(8).","DOI":"10.2165\/00002018-200831080-00006"},{"issue":"3","key":"1188_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/00005792-199505000-00004","volume":"74","author":"AS De Vriese","year":"1995","unstructured":"De Vriese AS, Philippe J, Van Renterghem DM, De Cuyper CA, Hindryckx PH, Matthys EG, Louagie A. Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature. Medicine. 1995;74(3):144\u201351.","journal-title":"Medicine."},{"issue":"6","key":"1188_CR7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1136\/jnnp.47.6.642","volume":"47","author":"DW Chadwick","year":"1984","unstructured":"Chadwick DW, Shaw MD, Foy P, Rawlins MD, Turnbull DM. Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. J Neurol, Neurosurg Psychiatry. 1984;47(6):642\u20134.","journal-title":"J Neurol, Neurosurg Psychiatry."},{"issue":"20","key":"1188_CR8","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1212\/01.wnl.0000261917.83337.db","volume":"68","author":"H Arif","year":"2007","unstructured":"Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology. 2007;68(20):1701\u20139.","journal-title":"Neurology"},{"issue":"2","key":"1188_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S1734-1140(13)71015-6","volume":"65","author":"B Blaszczyk","year":"2013","unstructured":"Blaszczyk B, Szpringer M, Czuczwar SJ, Lason W. Single centre 20 year survey of antiepileptic drug-induced hypersensitivity reactions. Pharmacol Rep. 2013;65(2):399\u2013409.","journal-title":"Pharmacol Rep"},{"issue":"1","key":"1188_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0749-0690(03)00032-6","volume":"18","author":"JR Sullivan","year":"2002","unstructured":"Sullivan JR, Shear NH. Drug eruptions and other adverse drug effects in aged skin. Clin Geriatr Med. 2002;18(1):21\u201342.","journal-title":"Clin Geriatr Med"},{"issue":"10","key":"1188_CR11","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jocn.2010.12.054","volume":"18","author":"C Locharernkul","year":"2011","unstructured":"Locharernkul C, Shotelersuk V, Hirankarn N. Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions. J Clin Neurosci. 2011;18(10):1289\u201394.","journal-title":"J Clin Neurosci"},{"issue":"6","key":"1188_CR12","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/j.jaip.2018.02.018","volume":"6","author":"H Guvenir","year":"2018","unstructured":"Guvenir H, Dibek Misirlioglu E, Civelek E, et al. The frequency and clinical features of hypersensitivity reactions to antiepileptic drugs in children: a prospective study. J Allergy Clin Immunol Pract. 2018;6(6):2043\u201350.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1188_CR13","first-page":"37","volume":"107","author":"C Beylot","year":"1980","unstructured":"Beylot C. Pustuloses exanthematiques aigues generalisees. Ann Dermatol Venereol. 1980;107:37\u201348.","journal-title":"Ann Dermatol Venereol."},{"issue":"7","key":"1188_CR14","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ajem.2017.02.017","volume":"35","author":"ZD Levy","year":"2017","unstructured":"Levy ZD, Slowey M, Schulder M. Acute generalized exanthematous pustulosis secondary to levetiracetam and valproic acid use. Am J Emerg Med. 2017;35(7):1036-e1.","journal-title":"Am J Emerg Med."},{"issue":"1","key":"1188_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000471842","volume":"9","author":"C Kley","year":"2017","unstructured":"Kley C, Murer C, Maul JT, Meier B, Anzengruber F, Navarini AA. Rapid involution of pustules during topical steroid treatment of acute generalized exanthematous pustulosis. Case Rep Dermatol. 2017;9(1):135\u20139.","journal-title":"Case Rep Dermatol."},{"issue":"5","key":"1188_CR16","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/bjd.13540","volume":"172","author":"S Ingen-Housz-Oro","year":"2015","unstructured":"Ingen-Housz-Oro S, Hotz C, Valeyrie-Allanore L, Sbidian E, Hemery F, Chosidow O, Wolkenstein P. Acute generalized exanthematous pustulosis: a retrospective audit of practice between 1994 and 2011 at a single centre. Br J Dermatol. 2015;172(5):1455\u20137.","journal-title":"Br J Dermatol."},{"issue":"5","key":"1188_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1365-4632.2010.04313.x","volume":"49","author":"HY Lee","year":"2010","unstructured":"Lee HY, Chou D, Pang SM, Thirumoorthy T. Acute generalized exanthematous pustulosis: analysis of cases managed in a tertiary hospital in Singapore. Int J Dermatol. 2010;49(5):507\u201312.","journal-title":"Int J Dermatol."},{"issue":"2","key":"1188_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5021\/ad.2010.22.2.163","volume":"22","author":"MJ Choi","year":"2010","unstructured":"Choi MJ, Kim HS, Park HJ, Park CJ, Lee JD, Lee JY, Kim HO, Park YM. Clinicopathologic manifestations of 36 Korean patients with acute generalized exanthematous pustulosis: a case series and review of the literature. Ann Dermatol. 2010;22(2):163.","journal-title":"Ann Dermatol."},{"issue":"4","key":"1188_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2340\/00015555-0438","volume":"88","author":"SL Chang","year":"2008","unstructured":"Chang SL, Huang YH, Yang CH, Hu S, Hong HS. Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in Asia. Acta Derm-Venereol. 2008;88(4):363\u20135.","journal-title":"Acta Derm-Venereol."},{"issue":"4","key":"1188_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.74","volume":"1","author":"M O\u2019Brian","year":"2021","unstructured":"O\u2019Brian M, Carr CL, Thomas C, Dominguez AR, Mauskar M. Clinical characteristics and management of acute generalized exanthematous pustulosis with haemodynamic instability. Skin Health Disease. 2021;1(4): e74.","journal-title":"Skin Health Disease."},{"issue":"1","key":"1188_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jaad.2020.02.069","volume":"83","author":"D Yanes","year":"2020","unstructured":"Yanes D, Nguyen E, Imadojemu S, Kroshinsky D. Cyclosporine for treatment of acute generalized exanthematous pustulosis: A retrospective analysis. J Am Acad Dermatol. 2020;83(1):263\u20135.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"1188_CR22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1468-3083.2006.02026.x","volume":"21","author":"F Meiss","year":"2007","unstructured":"Meiss F, Helmbold P, Meykadeh N, Gaber G, Marsch W, Fischer M. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-\u03b1 antibody infliximab: report of three cases. J Eur Acad Dermatol Venereol. 2007;21(5):717\u20139.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"8","key":"1188_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.758354","volume":"16","author":"L Zhang","year":"2021","unstructured":"Zhang L, Xu Q, Lin T, Ruan S, Lin M, Bao C, Zhang J, Liu T, Gong T, Ji C. Case report: successful treatment of acute generalized exanthematous pustulosis with secukinumab. Front Med. 2021;16(8): 758354.","journal-title":"Front Med."},{"issue":"2","key":"1188_CR24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1001\/jamadermatol.2021.5390","volume":"158","author":"A Creadore","year":"2022","unstructured":"Creadore A, Desai S, Alloo A, et al. Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US. JAMA Dermatol. 2022;158(2):176\u201383. https:\/\/doi.org\/10.1001\/jamadermatol.2021.5390.","journal-title":"JAMA Dermatol."},{"issue":"5","key":"1188_CR25","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","volume":"157","author":"A Sidoroff","year":"2007","unstructured":"Sidoroff A, Dunant A, Viboud C, Halevy S, Bouwes Bavinck JN, Naldi L, Mockenhaupt M, Fagot J-P, Roujeau J-C. Risk factors for acute generalized exanthematous pustulosis (AGEP)\u2014results of a multinational case\u2013control study (EuroSCAR). Br J Dermatol. 2007;157(5):989\u201396. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08156.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1188_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1592\/phco.31.4.440","volume":"31","author":"SM Sultan","year":"2011","unstructured":"Sultan SM, Daniels LM. Levetiracetam-Induced Acute Generalized Exanthematous Pustulosis. Pharmacotherapy: J Human Pharmacol Drug Therapy. 2011;31(4):440.","journal-title":"Pharmacotherapy: J Human Pharmacol Drug Therapy."},{"issue":"3","key":"1188_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1365-4632.2009.03908.x","volume":"48","author":"E Guevara-Gutierrez","year":"2009","unstructured":"Guevara-Gutierrez E, Uribe-Jimenez E, Diaz-Canchola M, Tlacuilo-Parra A. Acute generalized exanthematous pustulosis: report of 12 cases and literature review. Int J Dermatol. 2009;48(3):253\u20138.","journal-title":"Int J Dermatol."},{"issue":"1","key":"1188_CR28","first-page":"61","volume":"16","author":"S Skalli","year":"2011","unstructured":"Skalli S, Barret P, Villier C, Bussi\u00e8res JF. Carbamazepine-Induced Acute Generalized Exanthematous Pustulosis: A Case Report. J Pediatr Pharmacol Therap. 2011;16(1):61\u20135.","journal-title":"J Pediatr Pharmacol Therap."},{"issue":"7","key":"1188_CR29","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","volume":"124","author":"P Cacoub","year":"2011","unstructured":"Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588\u201397.","journal-title":"Am J Med."},{"key":"1188_CR30","doi-asserted-by":"crossref","unstructured":"Descamps V, Sa\u00efd BB, Sassolas B, Truchetet F, Avenel-Audran M, Girardin P, Guinnepain MT, Mathelier-Fusade P, Assier H, Milpied B, Modiano P. Prise en charge du drug reaction with eosinophilia and systemic symptoms (DRESS). In Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie. 2010;137(11): 703-708. Elsevier Masson.","DOI":"10.1016\/j.annder.2010.04.024"},{"issue":"4","key":"1188_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.18176\/jiaci.0480","volume":"30","author":"R Caba\u00f1as","year":"2020","unstructured":"Caba\u00f1as R, Ram\u00edrez E, Sendagorta E, Alamar R, Barranco R, Blanca-L\u00f3pez N, Do\u00f1a I, Fern\u00e1ndez J, Garcia-Nunez I, Garc\u00eda-Samaniego J, Lopez-Rico R. Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome. J Investig Allergol Clin Immunol. 2020;30(4):229\u201353.","journal-title":"J Investig Allergol Clin Immunol."},{"issue":"3","key":"1188_CR32","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/bjd.12125","volume":"168","author":"A Barbaud","year":"2013","unstructured":"Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, Grange A, Amarger S, Girardin P, Guinnepain MT, Truchetet F. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555\u201362.","journal-title":"Br J Dermatol."},{"issue":"4","key":"1188_CR33","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1365-2133.1997.tb02175.x","volume":"136","author":"P Redondo","year":"1997","unstructured":"Redondo P, De Felipe I, De la Pena A, Aramendia JM, Vanaclocha V. Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine. Br J Dermatol. 1997;136(4):645\u20136.","journal-title":"Br J Dermatol."},{"issue":"3","key":"1188_CR34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1034\/j.1600-0536.2003.00065.x","volume":"48","author":"AY Lee","year":"2003","unstructured":"Lee AY, Choi J, Chey WY. Patch testing with carbamazepine and its main metabolite carbamazepine epoxide in cutaneous adverse drug reactions to carbamazepine. Contact Dermatitis. 2003;48(3):137\u20139.","journal-title":"Contact Dermatitis."},{"issue":"1","key":"1188_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1046\/j.1365-2133.1998.02313.x","volume":"139","author":"RP Barbaud","year":"1998","unstructured":"Barbaud RP, Trechot JP, Ehlinger N, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol. 1998;139(1):49\u201358.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1188_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archderm.1989.01670140151033","volume":"125","author":"L Vaillant","year":"1989","unstructured":"Vaillant L, Camenen I, Lorette G. Patch testing with carbamazepine: reinduction of an exfoliative dermatitis. Arch Dermatol. 1989;125(2):29.","journal-title":"Arch Dermatol"},{"key":"1188_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12948-017-0072-5","volume":"15","author":"F De Luca","year":"2017","unstructured":"De Luca F, Losappio LM, Mirone C, Schroeder JW, Citterio A, Aversano MG, Scibilia J, Pastorello EA. Tolerated drugs in subjects with severe cutaneous adverse reactions (SCARs) induced by anticonvulsants and review of the literature. Clin Mol Allergy. 2017;15:1\u20138.","journal-title":"Clin Mol Allergy."},{"issue":"9","key":"1188_CR38","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.seizure.2010.09.003","volume":"19","author":"XQ Wang","year":"2010","unstructured":"Wang XQ, Lang SY, Shi XB, Tian HJ, Wang RF, Yang F. Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population. Seizure. 2010;19(9):562\u20136.","journal-title":"Seizure."},{"issue":"21","key":"1188_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2023.100583","volume":"11","author":"S Rahimi","year":"2023","unstructured":"Rahimi S, Danaei B, Nasehi MM, Saket S, Farahbakhsh N, Rajabnejad M, Taghdiri MM. Investigation of cross-reactivity between phenobarbital and levetiracetam in children with epilepsy: A prospective, observational multicenter study. Epilepsy Behav Rep. 2023;11(21): 100583. https:\/\/doi.org\/10.1016\/j.ebr.2023.100583.","journal-title":"Epilepsy Behav Rep."},{"issue":"suppl 1","key":"1188_CR40","first-page":"22","volume":"62","author":"AA Hebert","year":"2001","unstructured":"Hebert AA, Ralston JP. Cutaneous reactions to anticonvulsant medications. J Clin Psychiatry. 2001;62(suppl 1):22\u20136.","journal-title":"J Clin Psychiatry."},{"key":"1188_CR41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.seizure.2012.03.007","volume":"21","author":"A Alkhotani","year":"2012","unstructured":"Alkhotani A, McLachlan RS. Levetiracetam induced angioedema in a patient with previous anticonvulsant hypersensitivity reaction to phenytoin and lamotrigine. Seizure. 2012;21:407\u20138.","journal-title":"Seizure."},{"key":"1188_CR42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.pediatrneurol.2007.03.010","volume":"37","author":"JF Knudsen","year":"2007","unstructured":"Knudsen JF, Flowers CM, Kortepeter C, Awaad Y. Clinical profile of oxcarbazepine-related angioneurotic edema: case report and review. Pediatr Neurol. 2007;37:134\u20137.","journal-title":"Pediatr Neurol."},{"key":"1188_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4103\/0976-3147.105624","volume":"4","author":"R Mondal","year":"2013","unstructured":"Mondal R, Sarkar S, Sabui T, Pan PP. Phenytoin induced life threatening macroglossia in a child. J Neurosci Rural Pract. 2013;4:75\u20137.","journal-title":"J Neurosci Rural Pract."},{"issue":"2","key":"1188_CR44","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.pediatrneurol.2013.09.006","volume":"50","author":"E Koklu","year":"2014","unstructured":"Koklu E, Ariguloglu EA, Koklu S. Levetiracetam-induced anaphylaxis in a neonate. Pediatr Neurol. 2014;50(2):192\u20134.","journal-title":"Pediatr Neurol."},{"issue":"7","key":"1188_CR45","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1097\/PEC.0000000000000495","volume":"31","author":"I Polat","year":"2015","unstructured":"Polat I, Karaoglu P, Ayanoglu M, Yis U, Hiz S. Life-Threatening and Rare Adverse Effects of Phenytoin. Pediatr Emerg Care. 2015;31(7):e3. https:\/\/doi.org\/10.1097\/PEC.0000000000000495.","journal-title":"Pediatr Emerg Care"},{"issue":"4","key":"1188_CR46","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jaci.2009.08.025","volume":"124","author":"FE Simons","year":"2009","unstructured":"Simons FE. Anaphylaxis: recent advances in assessment and treatment. J Allergy Clin Immunol. 2009;124(4):625\u201336.","journal-title":"J Allergy Clin Immunol."},{"issue":"11","key":"1188_CR47","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/dmcn.12835","volume":"57","author":"O Toker","year":"2015","unstructured":"Toker O, Tal Y, Horev L, Shmoeli D, Gilboa T. Valproic acid hypersensitivity and desensitization. Dev Med Child Neurol. 2015;57(11):1076\u20138.","journal-title":"Dev Med Child Neurol."},{"issue":"9","key":"1188_CR48","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00228-022-03353-8","volume":"78","author":"A Chaabane","year":"2022","unstructured":"Chaabane A, Romdhane HB, Fadhel NB, Fredj NB, Ammar H, Boughattas N, Chadly Z, Aouam K. DRESS characteristics according to the causative medication. Eur J Clin Pharmacol. 2022;78(9):1503\u201310.","journal-title":"Eur J Clin Pharmacol"},{"issue":"138","key":"1188_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clineuro.2015.07.008","volume":"1","author":"XQ Wang","year":"2015","unstructured":"Wang XQ, Wang HF, Zhang X, Yu SY, Huang XS, Zhang JT, Tian CL, Lang SY. Lamotrigine induced DIHS\/DRESS: Manifestations, treatment, and outcome in 57 patients. Clin Neurol Neurosurg. 2015;1(138):1\u20137.","journal-title":"Clin Neurol Neurosurg."},{"issue":"1","key":"1188_CR50","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/17843286.2020.1767459","volume":"77","author":"C Mor\u00e1n-Mari\u00f1os","year":"2022","unstructured":"Mor\u00e1n-Mari\u00f1os C, Alva-Diaz C, De la Cruz Ramirez W, Quincho-Lopez A, Mori N, Pacheco-Mendoza J, Romero-S\u00e1nchez R. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by phenytoin re-exposure: case report and systematic review. Acta Clin Belg. 2022;77(1):177\u201385.","journal-title":"Acta Clin Belg."},{"issue":"18","key":"1188_CR51","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.3390\/jcm10184287","volume":"10","author":"D Jevtic","year":"2021","unstructured":"Jevtic D, Dumic I, Nordin T, Singh A, Sulovic N, Radovanovic M, Jecmenica M, Milovanovic T. Less known gastrointestinal manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review of the literature. J Clin Med. 2021;10(18):4287.","journal-title":"J Clin Med."},{"issue":"14","key":"1188_CR52","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.3390\/jcm12144576","volume":"12","author":"M Dagnon da Silva","year":"2023","unstructured":"Dagnon da Silva M, Domingues SM, Oluic S, Radovanovic M, Kodela P, Nordin T, Paulson MR, Joksimovi\u0107 B, Adetimehin O, Singh D, Madrid C. Renal manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review of 71 cases. J Clin Med. 2023;12(14):4576.","journal-title":"J Clin Med."},{"issue":"3","key":"1188_CR53","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/jcm11030704","volume":"11","author":"M Radovanovic","year":"2022","unstructured":"Radovanovic M, Jevtic D, Calvin AD, Petrovic M, Paulson M, Rueda Prada L, Sprecher L, Savic I, Dumic I. \u201cHeart in DRESS\u201d: cardiac manifestations, treatment and outcome of patients with drug reaction with eosinophilia and systemic symptoms syndrome: a systematic review. J Clin Med. 2022;11(3):704.","journal-title":"J Clin Med."},{"key":"1188_CR54","doi-asserted-by":"crossref","unstructured":"Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994;102(6).","DOI":"10.1111\/1523-1747.ep12388434"},{"issue":"42","key":"1188_CR55","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40264-018-0711-x","volume":"21","author":"N Frey","year":"2019","unstructured":"Frey N, Bodmer M, Bircher A, Jick SS, Meier CR, Spoendlin J. Stevens-Johnson syndrome and toxic epidermal necrolysis in association with commonly prescribed drugs in outpatient care other than anti-epileptic drugs and antibiotics: A population-based case\u2013control study. Drug Safety. 2019;21(42):55\u201366.","journal-title":"Drug Safety."},{"issue":"4","key":"1188_CR56","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1600-0536.1996.tb02364.x","volume":"35","author":"P Wolkenstein","year":"1996","unstructured":"Wolkenstein P, Chosidow O, Fl\u00e9chet M-L, Robbiola O, Paul M, Dume L, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis. 1996;35(4):234\u20136.","journal-title":"Contact Dermatitis"},{"key":"1188_CR57","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","volume":"428","author":"WH Chung","year":"2004","unstructured":"Chung WH, Hung SI, Hong HS, et al. A marker for Stevens-Johnson syndrome. Nature. 2004;428:486. https:\/\/doi.org\/10.1038\/428486a.","journal-title":"Nature"},{"key":"1188_CR58","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cpt.1190","volume":"105","author":"SC Su","year":"2019","unstructured":"Su SC, Chen CB, Chang WC, Wang CW, Fan WL, Lu LY, et al. HLA alleles and CYP2C9*3 as predictors of phenytoin hypersensitivity in east Asians. Clin Pharmacol Ther. 2019;105:476\u201385. https:\/\/doi.org\/10.1002\/cpt.1190.","journal-title":"Clin Pharmacol Ther."},{"key":"1188_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.759559","volume":"8","author":"SC Yang","year":"2021","unstructured":"Yang SC, Chen CB, Lin MY, Zhang ZY, Jia XY, Huang M, et al. Genetics of severe cutaneous adverse reactions. Front Med. 2021;8: 652091. https:\/\/doi.org\/10.3389\/fmed.2021.759559.","journal-title":"Front Med."},{"issue":"3","key":"1188_CR60","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1017\/S0317167100021880","volume":"24","author":"C Hyson","year":"1997","unstructured":"Hyson C, Sadler M. Cross sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci. 1997;24(3):245\u20139.","journal-title":"Can J Neurol Sci."},{"issue":"102","key":"1188_CR61","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.seizure.2022.09.011","volume":"1","author":"M Rashid","year":"2022","unstructured":"Rashid M, Rajan AK, Chhabra M, Kashyap A, Chandran VP, Venkataraman R, Nair S, Thunga G. Role of human leukocyte antigen in anti-epileptic drugs-induced Stevens-Johnson Syndrome\/toxic epidermal necrolysis: A meta-analysis. Seizure. 2022;1(102):36\u201350.","journal-title":"Seizure."},{"issue":"6","key":"1188_CR62","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/bjd.14530","volume":"174","author":"D Creamer","year":"2016","unstructured":"Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JK, Setterfield J, Bunker CB, Ardern-Jones MR, Watson KM, Wong GA. UK guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174(6):1194\u2013227.","journal-title":"Br J Dermatol."},{"key":"1188_CR63","first-page":"51","volume":"2","author":"B Michaels","year":"2009","unstructured":"Michaels B, del Rosso JQ. The role of systemic corticosteroid therapy in erythema multiforme major and stevens-johnson syndrome a review of past and current opinions. J Clin Aesthetic Dermatol. 2009;2:51.","journal-title":"J Clin Aesthetic Dermatol."},{"key":"1188_CR64","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","volume":"153","author":"S Zimmermann","year":"2017","unstructured":"Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, Mockenhaupt M. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatol. 2017;153:514\u201322.","journal-title":"JAMA Dermatol."},{"key":"1188_CR65","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/jid.2012.510","volume":"133","author":"P Sekula","year":"2013","unstructured":"Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bavinck JNB, Halevy S, Kardaun S, Sidoroff A, Liss Y, Schumacher M, et al. Comprehensive Survival Analysis of a Cohort of Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. J Investig Dermatol. 2013;133:1197\u2013204.","journal-title":"J Investig Dermatol."},{"key":"1188_CR66","doi-asserted-by":"publisher","first-page":"612","DOI":"10.12688\/f1000research.24748.1","volume":"9","author":"A Hasegawa","year":"2020","unstructured":"Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. F1000Research. 2020;9:612.","journal-title":"F1000Research"},{"issue":"5","key":"1188_CR67","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jpurol.2017.01.018","volume":"13","author":"JP Van Batavia","year":"2017","unstructured":"Van Batavia JP, Chu DI, Long CJ, Jen M, Canning DA, Weiss DA. Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Pediatr Urol. 2017;13(5):490-e1.","journal-title":"J Pediatr Urol."},{"key":"1188_CR68","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.282.5388.490","volume":"282","author":"I Viard","year":"1998","unstructured":"Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490\u20133.","journal-title":"Science"},{"key":"1188_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167120","volume":"11","author":"LP Ye","year":"2016","unstructured":"Ye LP, Zhang C, Zhu QX. The effect of intravenous immunoglobulin combined with corticosteroid on the progression of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis. PLoS One. 2016;11: e0167120.","journal-title":"PLoS One"},{"key":"1188_CR70","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.jid.2017.05.022","volume":"137","author":"C Gonz\u00e1lez-Herrada","year":"2017","unstructured":"Gonz\u00e1lez-Herrada C, Rodr\u00edguez-Mart\u00edn S, Cachafeiro L, et al. Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. J Invest Dermatol. 2017;137:2092\u2013100.","journal-title":"J Invest Dermatol"},{"key":"1188_CR71","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/JIR.S160964","volume":"11","author":"QX Ng","year":"2018","unstructured":"Ng QX, De Deyn M, Venkatanarayanan N, et al. A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis. J Inflamm Res. 2018;11:135\u201342.","journal-title":"J Inflamm Res"},{"key":"1188_CR72","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.jid.2018.03.1496","volume":"138","author":"MH Noe","year":"2018","unstructured":"Noe MH, Mostaghimi A, Rosenbach M, et al. Selective use of cyclosporine for Stevens-Johnson syndrome\/toxic epidermal necrolysis may exclude patients with poor prognostic factors. J Invest Dermatol. 2018;138:2068\u201372.","journal-title":"J Invest Dermatol"},{"key":"1188_CR73","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.dsi.2017.04.004","volume":"35","author":"Y-T Chen","year":"2017","unstructured":"Chen Y-T, Hsu C-Y, Chien Y-N, Lee W-R, Huang Y-C. Efficacy of cyclosporine for the treatment of Stevens-Johnson syndrome and Toxic Epidermal Necrolysis: Systemic review and meta-analysis. Dermatol Sin. 2017;35:131\u20137.","journal-title":"Dermatol Sin."},{"key":"1188_CR74","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/pde.13236","volume":"34","author":"J St John","year":"2017","unstructured":"St John J, Vladimir R, Kristina JL, et al. Successful use of cyclosporin A for stevens\u2013johnson syndrome and toxic epidermal necrolysis in three children. Pediatr Dermatol. 2017;34:540\u20136. https:\/\/doi.org\/10.1111\/pde.13236.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"1188_CR75","doi-asserted-by":"publisher","first-page":"9234","DOI":"10.1016\/j.jaci.2005.06.029","volume":"116","author":"RE Hunger","year":"2005","unstructured":"Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-\u03b1 treatment. J Allergy Clin Immunol. 2005;116(4):9234. https:\/\/doi.org\/10.1016\/j.jaci.2005.06.029.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1188_CR76","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/JCI93349","volume":"128","author":"CW Wang","year":"2018","unstructured":"Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, Chang CJ, Su SC, Hui RC, Chin SW, Huang LF. Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128(3):985\u201396.","journal-title":"J Clin Invest."},{"key":"1188_CR77","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","volume":"352","author":"P Wolkenstein","year":"1998","unstructured":"Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352:1586\u20139.","journal-title":"Lancet"},{"issue":"12","key":"1188_CR78","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1001\/archderm.1985.01660120074023","volume":"121","author":"D Kamanabroo","year":"1985","unstructured":"Kamanabroo D, Schmitz-Landgraf W, Czarnetzki BM. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol. 1985;121(12):1548\u20139. https:\/\/doi.org\/10.1001\/archderm.1985.01660120074023.","journal-title":"Arch Dermatol"},{"issue":"2","key":"1188_CR79","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1744-9987.1998.tb00094.x","volume":"2","author":"H Yamada","year":"1998","unstructured":"Yamada H, Takamori K, Yaguchi H, Ogawa H. A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis. Ther Apher. 1998;2(2):153\u20136. https:\/\/doi.org\/10.1111\/j.1744-9987.1998.tb00094.x.","journal-title":"Ther Apher"},{"issue":"11","key":"1188_CR80","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s001340051063","volume":"25","author":"A Furubacke","year":"1999","unstructured":"Furubacke A, Berlin G, Anderson C, Sj\u00f6berg F. Lack of significant treatment effect of plasma exchange in the treatment of drug induced toxic epidermal necrolysis? Intensive Care Med. 1999;25(11):1307\u201310.","journal-title":"Intensive Care Med"},{"issue":"1","key":"1188_CR81","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.jid.5701033","volume":"128","author":"M Mockenhaupt","year":"2008","unstructured":"Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35\u201344.","journal-title":"J Invest Dermatol."},{"key":"1188_CR82","doi-asserted-by":"publisher","first-page":"12215","DOI":"10.1016\/j.amjmed.2016.03.022","volume":"129","author":"MA Miliszewski","year":"2016","unstructured":"Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson Syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. Am J Med. 2016;129:12215. https:\/\/doi.org\/10.1016\/j.amjmed.2016.03.022.","journal-title":"Am J Med"},{"key":"1188_CR83","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jaip.2019.09.032","volume":"8","author":"MS Yang","year":"2020","unstructured":"Yang MS, Lee JY, Kim J, Kim GW, Kim BK, Kim JY, et al. Searching for the culprit drugs for Stevens-Johnson Syndrome and toxic epidermal necrolysis from a nationwide claim database in Korea. J Allergy Clin Immunol Pract. 2020;8:690\u20135. https:\/\/doi.org\/10.1016\/j.jaip.2019.09.032.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"1188_CR84","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.burns.2021.08.009","volume":"48","author":"P De Bustros","year":"2022","unstructured":"De Bustros P, Baldea A, Sanford A, Joyce C, Adams W, Bouchard C. Review of culprit drugs associated with patients admitted to the burn unit with the diagnosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Syndrome. Burns. 2022;48(7):1561\u201373.","journal-title":"Burns."},{"issue":"9171","key":"1188_CR85","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","volume":"353","author":"B Rzany","year":"1999","unstructured":"Rzany B, Correia O, Kelly J, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Lancet. 1999;353(9171):2190\u20134.","journal-title":"Lancet."},{"issue":"6","key":"1188_CR86","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.12669\/pjms.296.4385","volume":"29","author":"S Parveen","year":"2013","unstructured":"Parveen S, Javed M. Stevens Johnson syndrome associated with lamotrigine. Pak J Med Sci. 2013;29(6):1450\u20132.","journal-title":"Pak J Med Sci."},{"issue":"2\u20133","key":"1188_CR87","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.eplepsyres.2008.04.003","volume":"80","author":"S Alvestad","year":"2008","unstructured":"Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res. 2008;80(2\u20133):194\u2013200.","journal-title":"Epilepsy Res"},{"issue":"4","key":"1188_CR88","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/pde.14598","volume":"38","author":"KL Gleghorn","year":"2021","unstructured":"Gleghorn KL, Voigt C, Kelly B. Toxic epidermal necrolysis and Stevens-Johnson syndrome\/toxic epidermal necrolysis overlap in pediatric patients with a focus on newer antiepileptic drugs: A 25-year retrospective study at a single tertiary care center. Pediatr Dermatol. 2021;38(4):812\u20138.","journal-title":"Pediatr Dermatol."},{"key":"1188_CR89","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40780-016-0048-5","volume":"2","author":"J Abe","year":"2016","unstructured":"Abe J, Umetsu R, Mataki K, et al. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese adverse drug event report database. J Pharm Health Care Sci. 2016;2:14.","journal-title":"J Pharm Health Care Sci."},{"key":"1188_CR90","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.alit.2015.01.002","volume":"64","author":"J Abe","year":"2015","unstructured":"Abe J, Mataki K, Umetsu R, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: the Food and Drug Administration adverse event reporting system, 2004\u20132013. Allergol Int. 2015;64:277\u20139.","journal-title":"Allergol Int."},{"issue":"12","key":"1188_CR91","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/epi.14591","volume":"59","author":"EP Borrelli","year":"2018","unstructured":"Borrelli EP, Lee EY, Descoteaux AM, Kogut SJ, Caffrey AR. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US Food and Drug Administration Adverse Event Reporting System. Epilepsia. 2018;59(12):2318\u201324.","journal-title":"Epilepsia."},{"issue":"8","key":"1188_CR92","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1080\/14740338.2022.2045946","volume":"21","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Zhou W, Guo X, Chi L, Chen C, Guo Z, Liang J, Wei L, Chen X, Ye X, He J. Drug-induced Stevens-Johnson syndrome: a disproportionality analysis from the pharmacovigilance database of the World Health Organization. Expert Opin Drug Saf. 2022;21(8):1127\u201333. https:\/\/doi.org\/10.1080\/14740338.2022.2045946.","journal-title":"Expert Opin Drug Saf."},{"issue":"3","key":"1188_CR93","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1684\/epd.2021.1288","volume":"23","author":"TS Tensini","year":"2021","unstructured":"Tensini TS, Von Glehn CQ, Bettinotti MP, Iglehart B, de Paola L, Lohr A, Rodrigues M, Tensini FS, Braatz VL, Silvado CE. Cutaneous adverse reactions associated with antiseizure medication: clinical characteristics and implications in epilepsy treatment. Epileptic Disorders. 2021;23(3):466\u201375.","journal-title":"Epileptic Disorders."},{"issue":"19","key":"1188_CR94","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1212\/01.wnl.0000334295.50403.4c","volume":"71","author":"LJ Hirsch","year":"2008","unstructured":"Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor SR Jr, Bazil CW. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology. 2008;71(19):1527\u201334.","journal-title":"Neurology."},{"issue":"3","key":"1188_CR95","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","volume":"28","author":"A Sidoroff","year":"2001","unstructured":"Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)\u2013a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113\u20139. https:\/\/doi.org\/10.1034\/j.1600-0560.2001.028003113.x.","journal-title":"J Cutan Pathol."},{"issue":"1","key":"1188_CR96","first-page":"49","volume":"99","author":"S Sekhon","year":"2017","unstructured":"Sekhon S, Nedorost ST. Patch testing for adverse drug reactions. Cutis. 2017;99(1):49\u201354.","journal-title":"Cutis."},{"key":"1188_CR97","doi-asserted-by":"publisher","unstructured":"A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions - Barbaud - 2013 - British Journal of Dermatology - Wiley Online Library [Internet]. [cited 2021 Feb 14]. Available from: https:\/\/www.onlinelibrary.wiley.com\/ doi\/full\/https:\/\/doi.org\/10.1111\/bjd.12125","DOI":"10.1111\/bjd.12125"},{"issue":"1","key":"1188_CR98","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1600-0536.2009.01659.x","volume":"62","author":"F Santiago","year":"2010","unstructured":"Santiago F, Gon\u00e7alo M, Vieira R, Coelho S, Figueiredo A. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis. 2010;62(1):47\u201353.","journal-title":"Contact Dermatitis"},{"issue":"3","key":"1188_CR99","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1468-3083.2011.04418.x","volume":"27","author":"YT Lin","year":"2013","unstructured":"Lin YT, Chang YC, Hui RCY, Yang CH, Ho HC, Hung SI, et al. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. J Eur Acad Dermatol Venereol JEADV. 2013;27(3):356\u201364.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"1188_CR100","unstructured":"Gon\u00e7alo M, Coelho S, Figueiredo A (2006) Ascertaining patch test concentration in cutaneous adverse drug reactions to aminopenicillins and carbamazepine. In Journal of Investigative Dermatology 126, 67-67. 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA: NATURE PUBLISHING GROUP."},{"issue":"5","key":"1188_CR101","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1600-0536.1993.tb03560.x","volume":"29","author":"K Alanko","year":"1993","unstructured":"Alanko K. Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis. 1993;29(5):254\u20137.","journal-title":"Contact Dermatitis."}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01188-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-024-01188-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01188-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T05:30:37Z","timestamp":1738128637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-024-01188-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1188"],"URL":"https:\/\/doi.org\/10.1007\/s11882-024-01188-0","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"23 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Dr. Unaiza Faizan does not have any disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"12"}}